Sandu Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was INR 500.84 million compared to INR 540.77 million a year ago. Revenue was INR 503.66 million compared to INR 541.32 million a year ago. Net income was INR 12.49 million compared to INR 13.2 million a year ago. Basic earnings per share from continuing operations was INR 1.35 compared to INR 1.67 a year ago. Diluted earnings per share from continuing operations was INR 1.35 compared to INR 1.47 a year ago.